Following non-submission
AWMSG advice |
||
| Status: Not endorsed (Statement of Advice) | ||
In the absence of a submission from the holder of the marketing authorisation, epoetin alfa (Eprex®) cannot be endorsed for use within NHS Wales for the treatment of symptomatic anaemia (haemoglobin concentration of ≤ 10 g/dL) in adults with low- or intermediate-1-risk primary myelodysplastic syndromes (MDS) who have low serum erythropoietin (< 200 mU/mL). |
||
|
||
Medicine details |
||
| Medicine name | epoetin alfa (Eprex®) | |
| Formulation | 2000 IU/ml, 4000 IU/ml, 10000 IU/ml and 40000 IU/ml solution for injection | |
| Reference number | 3138 | |
| Indication | Treatment of symptomatic anaemia (haemoglobin concentration of ≤ 10 g/dL) in adults with low- or intermediate-1-risk primary myelodysplastic syndromes (MDS) who have low serum erythropoietin (< 200 mU/mL). |
|
| Company | Janssen-Cilag Ltd | |
| BNF chapter | Nutrition & blood | |
| Submission type | Non-submission | |
| Status | Not endorsed (Statement of Advice) | |
| Date of issue | 13/07/2017 | |